Skip to content

Effects of HIIT Following PTR Programme

Can High-Intensity Interval Training (HIIT) Reduce the Risk of Diabetes Relapse Following Discharge From the NHS Path to Remission Programme? - a Pilot Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07565935
Acronym
HIITpostLCD
Enrollment
20
Registered
2026-05-04
Start date
2026-05-01
Completion date
2027-05-01
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity & Overweight, Type 2 Diabetes

Brief summary

Caloric restriction programmes are highly effective and safe interventions for inducing rapid weight loss and improvements in glycaemic control. The landmark DiRECT study showed that 68% of people completing a caloric restriction intervention achieved remission of type 2 diabetes (T2D) by one year. Consequently, the NHS Path to Remission (PTR) programme was developed to stimulate diabetes remission in individuals that meet certain criteria. Unfortunately, long-term follow-up of the DiRECT study suggests that in the majority of participants that achieved remission, diabetes relapses within 5 years. This necessitates a focus on identifying methods to improve long-term maintenance of diabetes remission. High-intensity interval training (HIIT) involves several brief bursts of intense exercise, interspersed with recovery breaks, and is becoming increasingly popular. HIIT can cause improvements in cardiovascular fitness, reduce blood pressure, and lower body fat content in only a fraction of the time of traditional exercise methods. Specific to T2D, HIIT has been shown to improve pancreatic beta cell function, which is critically important for maintenance of long-term diabetes remission. This pilot study is being conducted to determine whether participating in a home-based HIIT training programme may help maintain beta cell function in individuals that have achieved diabetes remission following the NHS PTR programme. The study will take place at the Royal Derby Hospital. The intention is to recruit 20 participants from Derbyshire or Nottinghamshire that have achieved diabetes remission in the NHS PTR programme. Participants will be recruited following discharge from the programme and allocated to either perform a HIIT training programme (intervention group), or continue with usual care (control group) for 16 weeks. Before starting, participants will attend the research department to have initial measurements taken including bioimpedance, fasting bloods, an intravenous glucose tolerance test, muscle ultrasound, electromyography and cardiopulmonary exercise testing. Following this, those in the intervention group will be asked to perform a home-based HIIT training programme 3 times per week and record details of each session in a booklet. The control group will be asked to continue with their habitual levels of physical activity. Participants will be contacted regularly to ensure their safety and compliance.

Interventions

BEHAVIORALExercise

High-intensity interval training

Sponsors

University of Nottingham
Lead SponsorOTHER
Association of British Clinical Diabetologists
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Adults between the age of 18-70 years * Ability to provide informed consent * Completed the NHS Path to Remission programme and achieved diabetes remission (HbA1c \<48mmol/mol (6.5%), and off diabetes medications for at least three months)

Exclusion criteria

* BMI \> 40kg/m2 * Current participation in a formal exercise regime * Current pregnancy or breastfeeding * Uncontrolled hypertension (blood pressure \>160/100mmHg) * History of cardiovascular disease: * Symptomatic angina * Heart failure (class III/IV) * Significant arrhythmias * Right to left cardiac shunt * Recent acute coronary syndrome * Severe aortic valvular disease * Active cardiac infection * Background of the following respiratory diseases: * Pulmonary hypertension * Significant COPD * Uncontrolled asthma * History of malignancy undergoing current treatment or palliation * Presence of significant musculoskeletal, neurological or cerebrovascular disease * Any other medical condition deemed by the investigators to preclude inclusion into the study

Design outcomes

Primary

MeasureTime frameDescription
Pancreatic beta cell functionAssessed at baseline and then follow-up (16 weeks)Assessment of beta-cell function using insulin first phase response from an intravenous glucose tolerance test

Secondary

MeasureTime frameDescription
Insulin sensitivityAssessed at baseline and then follow-up (16 weeks)Measured during the intravenous glucose tolerance test (IVGTT) and calculated from fasting glucose and insulin using the homeostatic model of assessment for insulin resistance
Overall glycaemic controlAssessed at baseline and then follow-up (16 weeks)From measurement of glycated haemoglobin (HbA1c)
Body weightAssessed at baseline and then follow-up (16 weeks)Measurement of participant weight
Body compositionAssessed at baseline and then follow-up (16 weeks)Measurement of fat mass and fat-free mass using bioimpedance analysis
Skeletal muscle functionAssessed at baseline and then follow-up (16 weeks)Assessed using muscle strength (1 repetition maximum) testing and electromyography
Skeletal muscle structureAssessed at baseline and then follow-up (16 weeks)Using muscle ultrasonography to assess muscle thickness, cross sectional area and fibre pennation angle
Cardiorespiratory fitnessAssessed at baseline and then follow-up (16 weeks)Determined from be the highest rate of oxygen consumption obtained (VO2max) during a cardiopulmonary exercise test

Countries

United Kingdom

Contacts

CONTACTOluwaseun Anyiam
oluwaseun.anyiam1@nottingham.ac.uk+441332724605
PRINCIPAL_INVESTIGATORIskandar Idris

University of Nottingham

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026